Tafasitamab plus lenalidomide versus pola-BR, R2, and CAR T: Comparing outcomes from RE-MIND2, an observational, retrospective cohort study in relapsed/refractory diffuse large B-cell lymphoma Meeting Abstract
| Authors: | Nowakowski, G. S.; Yoon, D. H.; Mondello, P.; Joffe, E.; Fleury, I.; Peters, A.; Greil, R.; Ku, M.; Marks, R.; Kim, K.; Zinzani, P. L. L.; Trotman, J.; Sabatelli, L.; Huang, D.; Waltl, E. E.; Winderlich, M.; Ambarkhane, S.; Kurukulasuriya, N. C.; Cordoba, R.; Hess, G.; Salles, G. |
| Abstract Title: | Tafasitamab plus lenalidomide versus pola-BR, R2, and CAR T: Comparing outcomes from RE-MIND2, an observational, retrospective cohort study in relapsed/refractory diffuse large B-cell lymphoma |
| Meeting Title: | 63rd Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 138 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2021 Dec 11-14 |
| Meeting Location: | Atlanta, GA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2021-11-23 |
| Language: | English |
| ACCESSION: | WOS:000736398800181 |
| DOI: | 10.1182/blood-2021-148302 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 183 -- Hybrid meeting, also took place online -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work